| This week's sponsor is Premier Research. | |  | Beyond Intensity: The Full Impact of Fibromyalgia Pain
Patient-reported outcomes drive fibromyalgia drug research, and pain intensity is one measure of many. Download our white paper to gauge the many related symptoms. Premier Research. It's what we do. Best. |
Today's Rundown Featured Story | | | Thursday, February 22, 2018 Gilead’s Kite has struck a $3 billion deal to access Sangamo Therapeutics’ zinc finger nuclease (ZFN) technology. Kite will use the ZFN gene editing platform to create next-generation, off-the-shelf CAR-T therapies to cement its position as a long-term front-runner in the growing cell therapy space. |
|
|
| This week's sponsor is NYCEDC. | |  | |
Top Stories Thursday, February 22, 2018 Months after losing its hepatitis C collaboration with Janssen, Achillion is reducing its workforce by 20% in a bid to save cash. Thursday, February 22, 2018 GW Pharmaceuticals’ GWP42006 has failed to outperform placebo in a phase 2a focal seizure trial. The setback wiped 5% off GW’s stock and dented the prospects of the cannabidivarin candidate. Tuesday, February 20, 2018 Tumor-bearing humanized models are vital preclinical platforms for assessing human-specific immunotherapies. Review immediately transferable humanized model strategies for accelerating immunotherapy drug discovery programs. Thursday, February 22, 2018 Columbia University spinout Kallyope launched back in 2015 with $44 million and a mission: to understand how the gut communicates with the brain and discover therapeutic targets. Now, with another $66 million in the bank, the biotech plans to advance its pipeline programs and identify new candidates. Wednesday, February 21, 2018 John Davis, who headed early clinical development at Pfizer, joined Magenta Therapeutics as chief medical officer. Thursday, February 22, 2018 Takeda has added another early-stage research partnership as it reboots its R&D operations, this time teaming up with two Seattle-based academic centers in a project focused on its key targets of cancer, gastrointestinal disease and neurological disorders. Thursday, February 22, 2018 Clinical trial sponsors who fail to report study results on time to clinicaltrials.gov are now put under public scrutiny, thanks to a new online tracker devised by clinical trial transparency advocacy project AllTrials. Thursday, February 22, 2018 Regeneron eye drug Eylea has been a hit on the market for years. But now, the number of patients experiencing a rare side effect is climbing, and doctors don’t know why. | This week's sponsor is ExL Events. | |  | |
Resources Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Presented by: Box and USDM Life Sciences Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process. Sponsored by: RBC Wealth Management Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. | 
